2nd meeting on novel adjuvants currently in/close to human clinical testing: World Health Organization - Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2155-2163

  Kenney, Richard T ^a   Regina Rabinovich, N ^b   Pichyangkul, Sathit ^c   Price, Virginia L ^d   Engers, Howard D ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Malaria Vaccine Initiative   (United States)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d WORLD BANK   (United States)

Author keywords

Human clinical trials; Novel adjuvants; Preclinical testing; Review; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM POTASSIUM SULFATE; AS 02; AS 04; BACTERIAL TOXIN; CALCIUM; IMMUDAPTIN; IMMUNDAPTIN; ISCOM; LIPID A DERIVATIVE; MONTANIDE ISA 51; MONTANIDE ISA 720; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OIL; OLIGONUCLEOTIDE; OM 174; PHOSPHOLIPID DERIVATIVE; PHOSPHORYL LIPID A; QS 21; RC 529; SURFACTANT; UNCLASSIFIED DRUG; VIROSOME; WATER OIL CREAM;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CONFERENCE PAPER; CPG ISLAND; DENDRITIC CELL; DRUG RESEARCH; FRANCE; MEDICAL RESEARCH; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS; EMULSIONS; FRANCE; HUMANS; MINERALS; SURFACE-ACTIVE AGENTS; VACCINES; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 0037157237     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00091-9     Document Type: Conference Paper

References (26)

1. Novel adjuvants currently in clinical testing 2-4 November 1998, Foundation Merieux, Annecy, France: A meeting sponsored by the World Health Organization
2. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria
3. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
4. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines
5. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations
6. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine
7. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
8. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
9. Efficacy and safety of new adjuvants
10. Immunogenicity of four Plasmodium falciparum pre-erythrocytic antigens in Aotus lemurinus monkeys
11. A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte response in humans, implications for vaccination strategies
12. Human Phase 1 vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant
13. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
14. Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice
15. ® formulations in animal and primate models
16. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine
17. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity
18. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
19. Isolation and characterization of Rhesus blood dendritic cells using flow cytometry
20. Immunomodulation using bacterial enterotoxins
21. Mucosal vaccines: Non-toxic derivatives of LT and CT as mucosal adjuvants
22. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models
23. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen
24. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
25. Different stimulating effects of complement C3b and complete Freund's adjuvant on antibody response
26. Overview Vaccines